Breast Implant Settlement Calculator 2026: Estimate BIA-ALCL & Implant Claim Value
Use the Breast Implant Settlement Calculator to organize potential claim factors involving a confirmed BIA-ALCL diagnosis, textured implant exposure, serious implant complications, explant surgery, reconstruction revision, FDA-described systemic symptoms, medical expenses, lost income and other documented damages.
- Separates confirmed BIA-ALCL from systemic-symptom and other complication pathways.
- Captures implant manufacturer, model, texture, serial/lot information and recall history.
- Organizes pathology, explant, oncology, reconstruction and damages records.
- Uses FDA and federal-court sources without treating allegations as proven causation.
Get Your Breast Implant Claim Estimate
Answer the guided questions using your diagnosis, implant history, pathology, treatment, explant/revision records and documented losses.
Who May Need a Breast Implant Claim Review?
Potential claims are highly fact-specific and can depend on diagnosis, implant texture and model, manufacturer, pathology, surgery history, recall information, treatment, damages, causation evidence, state law and filing deadlines.
Facts That May Support Closer Review
- Confirmed BIA-ALCL supported by pathology or cytology
- History of textured breast implants or tissue expanders
- Known manufacturer, model, serial number or patient device card
- Explant surgery, capsulectomy, oncology treatment or reconstruction revision
- Documented medical expenses, wage loss or long-term monitoring
Claims Requiring More Review
- Systemic symptoms without a formal BIA-ALCL diagnosis
- Unknown implant manufacturer, model or surface texture
- Implants removed years ago with incomplete records
- Symptoms with multiple potential medical explanations
- Unclear diagnosis, discovery date or filing deadline
Illustrative Breast Implant Settlement Ranges
These figures preserve the broad educational tiers from the existing calculator. They are TortAdvisor editorial planning ranges—not official averages, court matrices, manufacturer offers or guaranteed payouts.
Confirmed Severe BIA-ALCL Claim
$500,000–$1M+Confirmed lymphoma, significant oncology treatment, major surgery, permanent impact, strong implant identification and substantial documented damages.
Editorial estimate only.Serious Implant Complication
$150,000–$500,000Major explant or reconstruction revision, serious complications, strong medical records and substantial expenses or lost income.
Editorial estimate only.Documented Systemic Symptoms / Complication
$25,000–$150,000Documented symptoms, treatment, explant history and measurable life impact without the proof associated with a confirmed lymphoma claim.
Causation may be more contested.Unclear Product, Diagnosis or Deadline
Case-specificIncomplete product history, uncertain implant texture, limited medical records or deadline concerns require individual review.
No reliable numeric estimate.BIA-ALCL: Diagnosis, Implant Texture & FDA Reporting
BIA-ALCL is a T-cell lymphoma that can develop in the capsule or fluid around a breast implant. FDA states that risk is higher with textured-surface implants than smooth-surface implants.
FDA’s currently published MDR review reports 1,380 BIA-ALCL cases through June 30, 2024. FDA’s prior death table reported 63 deaths through June 30, 2023. FDA cautions that MDR data cannot by themselves calculate true incidence or prove individual causation.
Common Presentation
FDA advises patients to discuss persistent swelling, a mass, pain or other changes around an implant with a clinician.
Texture Matters
FDA says BIA-ALCL risk is higher for textured implants than smooth implants.
Diagnosis Evidence
Pathology, cytology, CD30 testing, imaging and oncology records can be critical.
Breast Implant Illness Symptoms: What FDA Says
FDA lists reported systemic symptoms such as fatigue, memory or concentration problems, joint and muscle pain, hair loss, weight changes, anxiety and depression.
FDA’s review identified 10,318 MDRs meeting systemic-symptom search criteria from January 1, 2008 through June 30, 2024 after duplicates were removed. FDA states that the cause of these symptoms and the degree to which they may be related to implants remain unclear. BII is not currently recognized as a formal medical diagnosis and there are no specific accepted diagnostic criteria.
Evidence That Can Strengthen a Breast Implant Claim Review
- Patient device card with manufacturer, model, serial or lot number
- Implantation operative report
- Surface texture and manufacturer information
- Explant, capsulectomy and reconstruction records
- Pathology, cytology and CD30/ALK testing where applicable
- Oncology, hematology and imaging records
- Systemic-symptom and specialist records
- Photos and symptom timeline
- Medical bills and out-of-pocket costs
- Lost wages and reduced-earning documentation
- Therapy, counseling or caregiving expenses
- Scarring, pain and quality-of-life documentation
Allergan BIOCELL Textured Breast Implant MDL 2921
The U.S. District Court for the District of New Jersey continues to maintain Master Docket 2:19-md-2921. The court identifies Judge Brian R. Martinotti and Magistrate Judge Leda Dunn Wettre and directs users to PACER for the latest filings.
MDL 2921 does not establish liability or compensation for every claimant. Product identity, BIOCELL exposure, diagnosis, causation, law and damages remain case-specific.
Why the 2019 Allergan BIOCELL Recall Still Matters
FDA requested recall of specified Allergan BIOCELL textured breast implants and tissue expanders because of BIA-ALCL risk. At the time, FDA reported that its analysis showed the BIA-ALCL risk with Allergan BIOCELL textured implants was approximately six times the risk with textured implants from other manufacturers marketing in the United States.
FDA did not recommend routine removal of textured implants in patients without symptoms solely because of the recall due to surgical risks.
What Can Affect Breast Implant Settlement Value?
Diagnosis Strength
Confirmed BIA-ALCL with pathology and oncology records is materially different from a symptom-only claim.
Implant Identification
Manufacturer, model, texture, serial/lot number and recall status can determine which product allegations matter.
Treatment Burden
Explant surgery, capsulectomy, reconstruction revision, chemotherapy, radiation and monitoring can increase documented losses.
Economic Damages
Medical expenses, lost wages, reduced earning capacity, travel and future care may affect value.
Personal Impact
Scarring, pain, emotional distress and long-term limitations may be relevant where recoverable.
Causation & Legal Risk
Alternative explanations, experts, state law, deadlines and defendant-specific defenses can materially affect value.
Breast Implant Lawsuit Filing Deadlines
There is no single national statute of limitations for every breast implant claim. Deadlines can depend on state law, diagnosis, discovery of a potential connection, explant date, recall information and other facts.
Related TortAdvisor Resources
Breast Implant Settlement Calculator FAQ
What does the calculator estimate?
It organizes diagnosis, implant type, product identification, pathology, treatment, explant history, medical expenses, lost income and other damages into an educational range.
Is BIA-ALCL breast cancer?
No. FDA describes BIA-ALCL as a T-cell lymphoma, not cancer of breast tissue.
Are textured implants associated with higher risk?
Yes. FDA states BIA-ALCL risk is higher with textured-surface implants than smooth-surface implants.
Is breast implant illness a formal diagnosis?
FDA says BII is not currently recognized as a formal medical diagnosis and causation remains unclear.
Does an Allergan recall automatically create a lawsuit?
No. Recall status can matter, but a claim still depends on product identity, injury, causation, law, deadlines and damages.
Does using the calculator create an attorney-client relationship?
No. Representation requires acceptance by a licensed attorney and an engagement agreement.
Request a Free Breast Implant Case Review
If you were diagnosed with BIA-ALCL or experienced serious complications after breast implants, use the calculator to organize your records or request a confidential screening.
FDA & Federal Court Breast Implant Sources
FDA — BIA-ALCL Medical Device Reports
FDA’s published MDR review, including 1,380 reported BIA-ALCL cases through June 30, 2024 and reporting limitations.
Open FDA MDR review →FDA — BIA-ALCL Questions & Answers
FDA guidance on implant texture, symptoms, risk and device identification.
Open FDA Q&A →FDA — Systemic Symptoms / BII MDR Review
FDA’s review of systemic-symptom reports and current statement that BII is not a formal diagnosis.
Open FDA systemic-symptom review →FDA — Allergan BIOCELL Recall
FDA’s 2019 action requesting recall of specified Allergan BIOCELL textured implants and tissue expanders.
Open FDA recall announcement →FDA — Breast Implant Safety Requirements
FDA information on boxed warnings, patient decision checklists and patient device cards.
Open FDA safety page →District of New Jersey — MDL 2921
Official court page for Allergan BIOCELL Textured Breast Implant Products Liability Litigation.
Open MDL 2921 page →
